Pharmacokinetics and safety of recombinant anti‐RhD in healthy RhD‐negative male volunteers

summary In this first‐in‐man study, we assessed the pharmacokinetics, safety and tolerability of MonoRho, a human recombinant monoclonal anti‐RhD immunoglobulin G1 (IgG1) antibody. Eighteen RhD‐negative healthy male volunteers were randomized in two groups to receive a single administration of 300 µg of MonoRho either intravenously or intramuscularly. There were no symptoms of allergic or anaphylactic type reaction in any subject, and there was no evidence of any MonoRho‐related changes in laboratory safety parameters. None of the subjects mounted a detectable immune response to MonoRho. Serum samples were obtained up to 91 days after injection to measure anti‐D IgG concentrations by flow cytometry. After intramuscular administration of MonoRho, anti‐D IgG concentrations gradually increased reaching peak levels after a mean of 3·4 days. After 3 weeks, the mean anti‐D IgG concentrations after intravenous and intramuscular administration became virtually equal to each other and remained so thereafter. In both the treatment groups, the mean elimination half‐life was about 18 days and thus similar to that described for plasma‐derived anti‐D IgG. The bioavailability of MonoRho after intramuscular administration was estimated as 46%. The excellent tolerability and safety of MonoRho as well as its expected elimination half‐life supports the continued clinical development of this compound.